Biora Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results

Results from the Phase 1 clinical trial for BT-600 demonstrate precise drug delivery to the colon with low systemic exposure, supporting the clinical development plan

Company Secures Up to $16 Million in Financing from Existing Investors, Buoyed by BT-600 Results and Progress Toward BioJet Partnership